Evidence map›Paper›PMID 39845772›Full record

ReviewInternational journal of nanomedicine2025

Localized Drug Delivery in Different Gastrointestinal Cancers: Navigating Challenges and Advancing Nanotechnological Solutions.

Alexandru Madalin Hasan, Simona Cavalu, Ahmed Y Kira, Rabab S Hamad, Mustafa Ahmed Abdel-Reheim, Elsayed A Elmorsy, Attalla F El-Kott, Kareem Morsy, Ali S AlSheri, Sally Negm and 1 more

Abstract readReview
In one paragraph

Review in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Alexandru Madalin HasanDepartment of Preclinical Sciences, Faculty of Medicine and Pharmacy, University of Oradea, Oradea, 410087, Romania.
Simona CavaluDepartment of Preclinical Sciences, Faculty of Medicine and Pharmacy, University of Oradea, Oradea, 410087, Romania.
Ahmed Y KiraDepartment of Pharmaceutics, Faculty of Pharmacy, Delta University for Science and Technology, Gamasa, 11152, Egypt.ORCID 0000-0003-1495-0480
Rabab S HamadBiological Sciences Department, College of Science, King Faisal University, Al Ahsa, 31982, Saudi Arabia.
Mustafa Ahmed Abdel-ReheimDepartment of Pharmaceutical Sciences, College of Pharmacy, Shaqra University, Shaqra, 11961, Saudi Arabia.
Elsayed A ElmorsyDepartment of Pharmacology and Therapeutics, College of Medicine, Qassim University, Buraidah, 51452, Saudi Arabia.ORCID 0000-0001-6165-3847
Attalla F El-KottDepartment of Biology, College of Science, King Khalid University, Abha, Saudi Arabia.
Kareem MorsyDepartment of Biology, College of Science, King Khalid University, Abha, Saudi Arabia.
Ali S AlSheriDepartment of Biology, College of Science, King Khalid University, Abha, Saudi Arabia.
Sally NegmDepartment of Life Sciences, College of Science and Art, Mahyel Aseer, King Khalid University, Abha, 62529, Saudi Arabia.ORCID 0000-0001-8057-2022
Sameh SaberDepartment of Pharmacology, Faculty of Pharmacy, Delta University for Science and Technology, Gamasa, 11152, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Different types of cancers affect the gastrointestinal tract (GIT), starting from the oral cavity and extending to the colon. In general, most of the current research focuses on the systemic delivery of the therapeutic agents, which leads to undesired side effects and a limited enhancement in the therapeutic outcomes. As a result, localized delivery within gastrointestinal (GI) cancers is favorable in overcoming these limitations. However, the localized delivery via oral administration faces many challenges related to the complex structure of GIT (varied pH levels and transit times) as well as the harsh environment within tumor cells (hypoxia, efflux pumps, and acidity). To overcome these obstacles, nano-drug delivery systems (NDDs) have been designed and proved their potential by exploiting these challenges in favor of offering a specific delivery to the desired target. The current review begins with an overview of different GI cancers and their impact globally. Then, it discusses the current treatment approaches and their corresponding limitations. Additionally, the different challenges associated with localized drug delivery for GI cancers are summarized. Finally, the review discusses in detail the recent therapeutic and diagnostic applications of NDDs that have been conducted in oral, esophageal, gastric, colon, and liver cancers, aiming to offer valuable insights into the current and future state of utilizing NDDs for the local treatment of GI cancers.

Indexed as

Antineoplastic AgentsDrug Delivery SystemsGastrointestinal NeoplasmsNanoparticle Drug Delivery SystemAdministration, OralAnimalsHumansNanomedicineAntineoplastic AgentsNanoparticle Drug Delivery Systemgastrointestinal cancergastro-retentive delivery systemslocalized deliverystimuli-responsive nanomaterials

Identifiers

PMID39845772
PMCPMC11752831

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.